Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Microbix Biosystems Inc T.MBX

Alternate Symbol(s):  MBXBF

Microbix Biosystems Inc. develops and commercializes biological and technological solutions for human health and wellbeing. It enables the commercialization of diagnostic assays by making a range of critical ingredients and devices for the global diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment products (QAPs) that support clinical lab proficiency testing, enable assay development and validation, or help ensure the quality of clinical diagnostic workflows. Its segments include development, manufacturing and sales of products relating to the medical diagnostics industry, namely antigens as test ingredients, quality assessment products to help ensure the accuracy of test workflows and viral transport medium to enable collection of patient test samples and, and development and commercialization of novel and proprietary products or technologies, such as Kinlytic. Its Kinlytic urokinase is a biologic thrombolytic drug used to treat blood clots.


TSX:MBX - Post by User

Comment by rovaniemiroveron Nov 11, 2020 2:05pm
115 Views
Post# 31878470

RE:RE:RE:KRC Insights’ analyst Bruce Krugel

RE:RE:RE:KRC Insights’ analyst Bruce Krugelall equity research reports are paid for ... doesn't matter which shop does the report (nesbitt burns, dominion securities, mcleod young weir, tdsecurities, etc.) they are all paid for - direct cash or with a lead on a new equity placement where the commission covers the cost of research.  Fund managers who work with Adelaide Capital will see the report, as Adelaide will peddle it to drum up interest in the next equity issue by MBX which Adelaide and Industrial Alliance (the other research house covering MBX) will lead.  The funding will come after the share price pops on news of sales levels for VTM, QAPs or kinlytic deal.  My bet is that after a kinlytic deal, the share price pops strongly, and a new equity deal is done to help finance the production of VTM, QAPs and kinlytic.
<< Previous
Bullboard Posts
Next >>